Journal of Neurology

, Volume 257, Issue 4, pp 524–532

Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression

  • Sven Pålhagen
  • Hongshi Qi
  • Björn Mårtensson
  • Jan Wålinder
  • Ann-Kathrine Granérus
  • Per Svenningsson
Original Communication

DOI: 10.1007/s00415-009-5353-6

Cite this article as:
Pålhagen, S., Qi, H., Mårtensson, B. et al. J Neurol (2010) 257: 524. doi:10.1007/s00415-009-5353-6

Abstract

The biochemical basis of major depression (MD) in Parkinson’s disease (PD) is largely unknown. To increase our understanding of MD in PD patients, the levels of monoamine metabolites (HVA, 5-HIAA and MHPG), BDNF, orexin-A, IL-6 and corticosterone were examined in cerebrospinal fluid. The analyses were performed in MD patients with (n = 11) and without (n = 12) PD at baseline and after 12 weeks’ of treatment with the antidepressant citalopram, and in patients with solely PD (n = 14) at baseline and after 12 weeks. The major findings were that PD patients with MD had significantly lower baseline levels of MHPG, corticosterone and IL-6 when compared to patients with solely MD. In response to citalopram treatment, patients with solely MD exhibited an expected decrease in 5-HIAA and MHPG levels which was not found in PD patients with MD. Moreover, the levels of BDNF and IL-6 were lower in PD patients with MD compared with patients with solely MD after treatment with citalopram. Thus, the biochemical basis and the response to citalopram differ between PD patients with MD and patients with solely MD.

Keywords

Parkinson’s diseaseMajor depressionCerebrospinal fluidBiomarkerHVA5-HIAAMHPGBDNFCorticosteroneIL-6CitalopramSSRI

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sven Pålhagen
    • 1
    • 2
  • Hongshi Qi
    • 3
  • Björn Mårtensson
    • 1
  • Jan Wålinder
    • 4
  • Ann-Kathrine Granérus
    • 5
  • Per Svenningsson
    • 1
    • 2
    • 3
  1. 1.Section of Clinical NeuroscienceKarolinska InstituteStockholmSweden
  2. 2.Department of NeurologyKarolinska University HospitalStockholmSweden
  3. 3.Section of Translational Neuropharmacology, Department of Physiology and Pharmacology, Center for Molecular MedicineKarolinska InstituteStockholmSweden
  4. 4.Department of PsychiatryGöteborg UniversityMölndalSweden
  5. 5.Division of Geriatrics, Department of Clinical and Experimental Medicine, Faculty of Health ScienceLinköping UniversityLinköpingSweden